Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feng Jia

Showing results (411-420 of 412) with videos related to

Pageof 42
Sort By:
You have reached the last page of results.This site can display upto 412 results.
Signal Transduction and Targeted Therapy|January 30, 2023
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trialHuijie Bian, Liang Chen, Zhao-Hui Zheng, et al.
Signal Transduction and Targeted Therapy|April 13, 2025
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trialHuijie Bian, Liang Chen, Zheng Zhang, et al.
Pageof 42

Showing results (411-420 of 412) with videos related to

Sort By:
Pageof 42
You have reached the last page of results.This site can display upto 412 results.
Signal Transduction and Targeted Therapy|January 30, 2023
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trialHuijie Bian, Liang Chen, Zhao-Hui Zheng, et al.
Signal Transduction and Targeted Therapy|April 13, 2025
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trialHuijie Bian, Liang Chen, Zheng Zhang, et al.
Pageof 42